Sorted libraries of error-free long oligonucleotides

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$200,625.00
Award Year:
2013
Program:
SBIR
Phase:
Phase I
Contract:
1R43DK099853-01
Agency Tracking Number:
R43DK099853
Solicitation Year:
2013
Solicitation Topic Code:
NIDDK
Solicitation Number:
PA12-088
Small Business Information
BIOPAL, INC
80 WEBSTER ST, WORCESTER, MA, -
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
9796223
Principal Investigator:
ERNEST GROMAN
(508) 770-1190
EVGroman@aol.com
Business Contact:
ERNEST GROMAN
(508) 770-1190
EVGroman@aol.com
Research Institution:
Stub




Abstract
DESCRIPTION (provided by applicant): Iron deficiency is frequently encountered in chronic kidney disease (CKD) patients and many other populations. Current oral iron formulations are poorly tolerated. Injectable iron preparations are difficult to administer, costly and have serious adverse reactions. Therefore, a highly absorbable, well tolerated oral iron supplement for the treatment of anemia associated with chronic kidney disease (CKD) is needed to complement erythropoiesis-stimulating agents. Our ironreplacement agent will have the following attributes: 1) oral delivery with minimal adverse events, 2) efficient intestinal transit with vascular system entry, 3) liver targeting where the iron is released to normal iron stores and 4) cost-effective manufacture providing savings to the medical economy. Our Phase I SBIR application is designed to synthesize prototype products fitting this description. This will be accomplished by applying the company's nano-technology expertise to develop a stable iron oxidecolloid having a surface coating to permit intestinal transport while protecting against bacterial bloom within th gut. Our proposed product is expected to be the first commercially feasible oral iron replacement therapy that can be safely self-administrated by the patient. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: This project will develop an oral iron supplement to more effectively treat iron deficient patients, a common occurrence in chronic kidney disease. The advantage of this product will be its low cost and the easy-of-use. This product is expected to be the first commercially feasible method that will allow patients to self-treat iron deficiency.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government